Summary.-Cell mediated immunocompetence was measured serially in 35 patients with malignant melanoma in order to determine the effect of extent of disease and prognosis as well as the influence of BCG immunotherapy on immune reactivity.
Compared with normal adult controls, statistically significant lymphopenia occurred only in patients with widespread disease. Seventeen of 21 patients with negative pre-therapy PPD skin test converted to skin test positivity. PHA blastogenesis was depressed only in patients in the pre-terminal stages of their disease using optimal mitogen concentrations for stimulation. Threshold concentrations of this mitogen more clearly demonstrated a depressed responsiveness which correlated in severity with extent of disease. PPD induced blastogenesis was normal or increased in the majority of patients; however, the degree of stimulation by PPD was less in the BCG induced convertors than in those patients who were skin test positive before BCG treatment. Comparison of the pre-and post BCG assessments reveals no significant differences except in relation to PPD conversion. We conclude that using threshold concentrations of PHA, impaired responses are regularly associated with disease beyond the regional lymph nodes. Routine assessment of lymphocyte function by these parameters did not provide information that was not available from clinical evaluation.
WHILE it has been known for many years that advanced cancer is associated with a failing immune system and, con- versely, that intact immune competence is associated with a more favourable outcome, the observations of Eilber and Morton in 1970 Immunological studies.-Total lymphocyte counts were performed monthly as part of the routine haematological assessment.
Purified protein derivative (PPD, Connaught Laboratories, 5TU) skin tests were performed before starting therapy and at monthly intervals thereafter. Candida (Hol- lister-Stier Laboratories, 1: 100) and mumps (Eli Lilly and Co., 2 u) were administered before starting therapy and at 3-monthly intervals thereafter. Initial skin tests were read by one of us, but subsequently the patients were instructed in reading their own skin tests with the aid of a card template. To confirm the presence of anergy, contact sensitization with DNCB was performed (Catalona et al., 1972) .
Peripheral blood lymphocytes were cultured without separation using a modification of the method of Junge et al. (1970) . Each culture consisted of 0-05 ml of heparinized whole blood in 1-95 ml of RPMI 1640 without added antibiotics or serum.
Mitogen responses were assessed by the addition of phytohaemagglutinin (PHA-P, Difco) in final concentrations previously determined to give (a) maximal and (b) threshold stimulation responses in normal subjects. These concentrations varied from bottle to bottle of PHA and had to be individually determined for each lot. A typical dose response curve based on titrations of one lot of PHA with 13 normal donors is shown in Fig. 1 . The concentrations used for optimal and threshold stimulation would be 10 and 0-3 ,ug/ml respectively. Triplicate cultures were incubated at 370C in 5%C02 for 67 h, at which time 2 ,uCi of tritiated thymidine (specific activity 6-7 Ci/mmol) were added to each culture. After 5 h further incubation, the cultures were terminated by the addition of 450 ,ug of cold thymidine and were placed immediately at -20°C.
Incorporation of radioactive thymidine was determined by a previously described method (Dent, 1971) , with the modification that the cell pellet containing intact erythrocytes was washed once with 3% acetic acid and once with normal saline before digestion with trichloracetic acid.
Proliferative responses to PPD in vitro were measured with the same technique, except that cultures were exposed to PPD (Connaught Laboratories-CT68) for 115 h before pulsing with tritiated thymidine. PPD was used at a final concentration of 10 and 1 ,tg/ml.
Statistical analysis.-Comparisons between patient groups and controls were made using the Student's unpaired t test. To determine the effect of BCG on the parameters measured, the pre-BCG response was compared with the mean ofthe post-BCGresponses using the paired t test. A P value of <0-05 was considered significant.
RESULTS

Clinical staging
The patients were divided into 4 groups. Group A (83 observations) included all patients without evidence of residual disease at the time of testing. The majority of these patients had had recurrences which were removed surgically. Group B (53 observations) included patients with local recurrences and/or regional node involvement. Group C (28 observations) included patients with metastatic disease beyond the regional lymph nodes. Group D (10 observations) was a retrospective categorization and included observations performed in the 6-week preterminal period before the death of the patient.
Peripheral lymphocyte levels
The normal total circulating lymphocyte level was 1906/mm3. In Fig. 2 it can be seen that there is a progressive decrease in circulating lymphocyte count with advancing disease. The lymphocyte level of patients in Group C is 1346/mm3 which is significantly lower than that of controls (P < 0.01). There is a slight rise in preterminal patients (Group D) but this is not significantly different from the mean lymphocyte level of patients in Group C. As determined by the size of the PPD skin test reaction, no differences could be detected among Groups A, B and C.
Phytohaemagglutinin stimulation
The in vitro lymphocyte blastogenic response to optimum stimulating concentrations of PHA are shown in Fig. 3 (Fig. 4) , which was clearly related to the extent of disease.
The levels of unstimulated thymidinc incorporation are shown in Fig. 5 
Effect of BOG therapy
The effect of BCG therapy on the immunological parameters studied are summarized in Fig. 7 . The values for UN' 400 circulating lymphocytes, optimal and threshold PHA response and in vitro PPD stimulation before and after therapy (mean of several estimations) were compared using the paired t test. The PPD results of pre-therapy skin test negative and positive patients are examined separately.
The only significant change occurred in those patients who converted from PPD negative to PPD positive. It is of interest that these patients never achieved the same degree of hyperreactivity which was noted in the patients who were PPD positive before BCG therapy. There was a consistent trend toward decreased reactivity in all other parameters in the post-BCG state but these differences did not reach statistical Balcerzak and LoBuglio, 1973; Finkel and Dent, 1973) . The mechanism of impaired reactivity to threshold PHA concentrations is not clear but it has been suggested that the response to threshold concentrations of PHA is dependent on macrophages (Oppenheim, Leventhal and Hersh, 1968) . It may be, therefore, that the impaired threshold response noted in these studies reflects an abnormality of macrophages rather than lymphocytes, a finding in keeping with the recent report of abnormal monocyte chemotaxis in patients with cancer (Boetcher and Leonard, 1974) . Further studies are required to determine if defective monocyte chemotaxis and impaired threshold PHA responses are directly related. Previous studies of cell mediated immunity have not revealed any consistent defects in patients with malignant melanoma. Ziegler et al. (1969) found no impairment of response to skin tests, DNCB sensitization or PHA response in vitro. Siegler et al. (1973) , in a more intensive study of patients with more far advanced disease, found a decrease in delayed hypersensitivity skin test reactivity. In vitro stimulation tests with PHA failed to reveal any abnormalities. reported that 69% of patients with melanoma had impaired DNCB reactivity; 25% of these were totally anergic. There was no difference in the frequency of impairment among patients with localized or metastatic disease. Catalona, Sample and Chretien (1973) Golub, O'Connell and Morton (1974) reported that patients with melanoma as a group have a significantly depressed response to mitogen stimulation with a much lower rate of anergy to DNCB sensitization (180 %).
Their findings resemble more closely those which we have presented in this report.
The effect of BCG therapy on immunological reactivity is a subject of great importance since, apart from survival or measurable disease regression, it is another parameter by which to gauge the possible effectiveness of this form of therapy. Bluming et al. (1972) have reported that BCG therapy by dermal scarification had a nonspecific potentiating effect on development of contact sensitivity to picryl chloride and on the recall of skin test reactivity to other skin test antigens which was not seen when lower doses of BCG were given by intradermal inoculation. No change in peripheral lymphocyte levels was noted. Chess et al. (1973) reported an increase in in vitro responses to recall antigens but no increase in PHA or mixed leucocyte reactivity. Gutterman et al. (1973) Finally, while we have shown that the extent of disease does correlate with a number of parameters of host responses, we do not feel that the information obtained is of any assistance in the management of the patient with cancer. As yet, there is little evidence that any form of immunotherapy produces a quantifiable effect on general immune competence that correlates with patient survival. While it is of interest, though not universally true (Chakravorty et al., 1973; Greene, Schimpff and Wernik, 1974) , that intact immune reactivity correlates with good prognosis (Harris and Copeland, 1974) , this knowledge does little to help the clinician in making management decisions about individual patients. Until we are able regularly and predictably to influence immunocompetence of cancer patients, the routine and widespread performance of tests of nonspecific immunocompetence should be discouraged.
